Patents by Inventor Xavier CARNEC

Xavier CARNEC has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity
    Patent number: 11638751
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 2, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM
    Publication number: 20210205436
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Application
    Filed: November 30, 2020
    Publication date: July 8, 2021
    Inventors: Sylvain BAIZE, Audrey PAGE, Xavier CARNEC, Mathieu Jean Simon MATEO, Stephanie REYNARD, Alexandra FIZET
  • Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
    Patent number: 10849969
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 1, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM
    Publication number: 20180303927
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Application
    Filed: October 24, 2016
    Publication date: October 25, 2018
    Inventors: Sylvain BAIZE, Audrey PAGE, Xavier CARNEC, Mathieu Jean Simon MATEO, Stephanie REYNARD, Alexandra FIZET
  • CD300A RECEPTORS AS VIRUS ENTRY COFACTORS
    Publication number: 20170000849
    Abstract: The present invention concerns an inhibitor of an interaction between CD300a and an aminophospholipid for use in preventing or treating a virus infection by inhibition of the interaction between CD300a and viral aminophospholipid.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 5, 2017
    Inventors: Ali AMARA, Xavier CARNEC, Laurent MEERTENS